Fact CheckerSign in

NCT07281664Not yet recruiting

Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Transarterial Chemoembolization Combined With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase II, Single-Arm Clinical Trial

Source: ClinicalTrials.gov · Last updated 15 Dec 2025

Brief summary (registry, in English)

This study aims to evaluate the safety and effectiveness of a combined treatment for patients with unresectable hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery. The treatment includes transarterial chemoembolization (TACE), which delivers chemotherapy directly into the liver tumor, together with low-dose bevacizumab and atezolizumab, two medicines that help the immune system fight cancer and inhibit tumor blood vessel growth. All participants in this study will receive the same combination treatment as their first-line therapy. The study will observe how well the tumor responds, how long the treatment can control the cancer, and what side effects may occur. The goal is to learn whether this combined approach can provide clinical benefit and improve outcomes for patients with advanced, unresectable liver cancer.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
30 (estimated)
First submitted
27 Nov 2025
Start date
1 Jan 2026
Primary completion date
31 Dec 2028
Lead sponsor
Third Affiliated Hospital, Sun Yat-Sen University
NCT number
NCT07281664

What you commit to

  • Study type: Interventional
  • Planned participants: 30
  • From 1 Jan 2026 to the primary completion date, 31 Dec 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Evidence or history of bleeding diathesis or any hemorrhage or bleeding event \>CTCAE grade 3 within 4 weeks prior to randomization;
  • A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment;

Other illness

  • Any condition representing a contraindication to TACE or I-125 seeds brachytherapy as determined by the investigators;
  • Active or history of autoimmune disease or immune deficiency;
  • Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding;
  • Evidence of bleeding diathesis or significant coagulopathy;
  • Significant cardiovascular disease;
  • Severe infection, such as active tuberculosis;
  • History of organ or cells transplantation;
  • History of other uncurable malignancies.

Other

  • Diffuse HCC;
  • Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular/cholangiocarcinoma subtypes (confirmed by histology, or pathology) are not eligible;
  • Evidence of extrahepatic spread (EHS);
  • Pregnant or breastfeeding females;
  • Serious medical comorbidities;

Who the study is looking for

  • Age between18 and 75 years;
  • Has a diagnosis of HCC confirmed by radiology, histology, or cytology;
  • Child-Pugh class A;
  • Eastern Cooperative Group performance status (ECOG) score of 0-1;
  • No prior systemic therapy for HCC.
  • Adequate hematologic and end-organ function;
  • At least one measurable intrahepatic target lesion.

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.